Compare Charles River Laboratories Intl. Inc (CRL) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Otis Worldwide Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $287.43 (market cap $13.46B), while Otis Worldwide Corp trades at $74.25 (market cap $27.80B). The key difference: Otis Worldwide Corp is far larger — about 2.1× Charles River Laboratories Intl. Inc's market cap, and Otis Worldwide Corp pays a 2.41% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | OTIS | |
|---|---|---|
Market Cap | $13.46B | $27.80B |
Sector | Health | Industrials |
52-Week High | $284.37 | $93.62 |
52-Week Low | $145.57 | $69.34 |
Enterprise Value | $16.30B | $35.84B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Otis Worldwide (OTIS) trades at $73.82, up 1.3% for the day, with a neutral technical signal. Recent Q2 2026 earnings showed a beat on EPS but included guidance cuts, reflecting margin pressures from labor costs. The company maintains strong service segment growth, with modernization revenue up 24%, though new equipment demand remains weak. Cash flow trends show variability, with 2025 net cash flow negative $1.22 billion due to financing activities, while 2026 projects a positive $146 million.
The investment outlook is mixed; analyst consensus is a Buy with a $92.50 price target, implying significant upside, but risks include persistent margin compression and economic sensitivity. The stock's current valuation below historical averages presents a potential opportunity if service margins stabilize and growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
